Quick Answer
SAB Biotherapeutics, Inc. reported Cash and Equivalents of $10.50 million for fiscal year 2025.
SAB Biotherapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $10.50M | +18.0% |
| 2024 | $8.90M | -84.3% |
| 2023 | $56.57M | +275.9% |
| 2022 | $15.05M | -9.4% |
| 2022 | $16.62M | -25.8% |
| 2022 | $22.41M | -32.5% |
| 2021 | $33.21M | +163.3% |
| 2020 | $12.61M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $29.42M | +220.8% | +696.9% |
| June 30, 2025 | $3.69M | -78.6% | -34.5% |
| March 31, 2025 | $5.64M | -59.8% | -36.6% |
| December 31, 2024 | $8.90M | -84.3% | -3.0% |
| September 30, 2024 | $9.17M | +278.1% | -46.8% |
| June 30, 2024 | $17.24M | +121.8% | +22.9% |
| March 31, 2024 | $14.03M | +7.5% | -75.2% |
| December 31, 2023 | $56.57M | +275.9% | +2232.2% |
- SAB Biotherapeutics, Inc. showed an increase of +18.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, SAB Biotherapeutics, Inc.’s cash and equivalents has declined by 16.7% (from $12.61 million to $10.50 million).
- The most recent figure is from SAB Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: